StockData

Artiva Biotherapeutics vs Celldex Therapeutics

ARTV and CLDX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How ARTV and CLDX compare

Celldex Therapeutics is the larger company, worth 12 times as much as Artiva Biotherapeutics ($2.2B against $189M).

Artiva Biotherapeutics scores higher on the StockData Score (8 against 7 for Celldex Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricARTVCLDX
Size and price
Market cap$189M$2.2B
Share price$3.86$28.04
Change, 1 year18.8%9.7%
Change, 5 years–−29.2%
Beta (5Y)4.841.03
Employees104198
StockData Score
Total score8 (better)7
Valuation score1 (better)0
Growth score00
Performance score11
Health score66
Dividend score00
Valuation
P/S–13937×
P/B0.5× (better)3.1×
FCF yield−40.8%−11.0% (better)
Growth
Revenue growth (TTM)–−97.3%
Revenue growth, 5Y average–−26.9%
Profitability
Operating margin–−206220%
Net margin–−190221%
FCF margin–−153231%
Return on equity−36.6% (better)−43.9%
Return on invested capital−3203%−2335% (better)
Financial health
Debt / equity0.000.00
Current ratio24.16 (better)11.82
Altman Z-score4.1615.62 (better)
Piotroski F-score12 (better)
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions83.2%109%
Held by insiders68.3%0.41%
Insider net buying, 12 months$106M (better)−$121K
Superinvestors holding1–
Short interest, % of float19.0%12.7%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.